Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 05/15/2026 | PUT | $7.00 | 651 | +98 | +17.72% |
| 05/15/2026 | CALL | $8.00 | 2,598 | +32 | +1.25% |
| 05/15/2026 | CALL | $5.00 | 14 | +10 | +250.00% |
| 05/15/2026 | PUT | $6.00 | 4,599 | +10 | +0.22% |
| 08/21/2026 | PUT | $7.00 | 290 | +10 | +3.57% |
| 09/18/2026 | CALL | $9.00 | 44 | +10 | +29.41% |
| 04/17/2026 | CALL | $6.00 | 154 | -2 | -1.28% |
| 05/15/2026 | PUT | $12.00 | 8 | -3 | -27.27% |
| 08/21/2026 | CALL | $10.00 | 1,019 | -10 | -0.97% |
| 04/17/2026 | CALL | $5.00 | 47 | -15 | -24.19% |
| 04/17/2026 | CALL | $7.00 | 1,785 | -17 | -0.94% |
| 04/17/2026 | PUT | $8.00 | 175 | -61 | -25.85% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.61% | 1.07M | 3.63M |
| iShares Russell 2000 ETF | 2.15% | 842.16k | 2.85M |
| Vanguard Extended Market Index Fund | 1.25% | 516.11k | 1.74M |
| iShares Russell 2000 Value ETF | 0.85% | 333.25k | 1.13M |
| Fidelity Small Cap Index Fund | 0.72% | 297.63k | 1.01M |
| Fidelity Extended Market Index Fund | 0.49% | 200.78k | 678.65k |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.36% | 149.4k | 504.97k |
| Vanguard Russell 2000 Index Fund | 0.24% | 97.33k | 328.99k |
| Schwab Capital Trust-Small Cap Index Fund | 0.21% | 84.74k | 286.43k |
| College Retirement Equities Fund-Stock Account | 0.21% | 87.97k | 297.33k |
| iShares Micro Cap ETF | 0.19% | 79.38k | 268.3k |
| Fidelity Total Market Index Fund | 0.14% | 59.57k | 201.36k |
| Quantitative Master Series Tr-Master Small Cap Index Series | 0.13% | 52.1k | 176.09k |
| TIAA-CREF Funds-Small-Cap Blend Index Fund | 0.13% | 52.71k | 178.17k |
| EQ Advisors Trust-EQ/2000 Managed Volatility Port | 0.10% | 42.44k | 143.44k |
| Fidelity Series Total Market Index Fund | 0.09% | 38.73k | 130.92k |
| TIAA-CREF Funds-Equity Index Fund | 0.08% | 34.91k | 118k |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.07% | 30.81k | 104.15k |
CorMedix Builds a Real Revenue Story as DefenCath Adoption Accelerates
12/24 04:42 am
Investing.com
Read moreAmerican Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative Solutions
11/21 10:00 am
GlobeNewswire Inc.
Read moreStrong Earnings and Biotech Resilience Define the Midweek Momentum
11/12 12:00 pm
GlobeNewswire Inc.
Read moreCorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
09/29 08:30 am
Benzinga
Read moreCorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
09/02 07:30 am
Benzinga
Read moreClosed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMR
12/10 03:45 am
GlobeNewswire Inc.
Read moreHere's Why CorMedix Is a Great 'Buy the Bottom' Stock Now
09/09 04:06 pm
Benzinga
Read moreCorMedix Inc. Announces New Commercial Agreement
09/09 10:52 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
06/06 08:30 am
GlobeNewswire Inc.
Read moreCorMedix (CRMD) Q1 2024 Earnings Call Transcript
05/09 11:00 am
The Motley Fool
Read moreCorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
05/09 07:30 am
GlobeNewswire Inc.
Read moreDoes CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
05/02 09:55 am
Zacks Investment Research
Read moreCorMedix Inc. Announces CMS Grants TDAPA to DefenCath
04/19 08:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
04/15 08:30 am
GlobeNewswire Inc.
Read moreWall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
04/11 09:55 am
Zacks Investment Research
Read moreCorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
04/08 08:30 am
GlobeNewswire Inc.
Read moreCorMedix (CRMD) Q4 2023 Earnings Call Transcript
03/12 04:15 pm
The Motley Fool
Read moreCorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
03/06 09:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Commercial and Reimbursement Updates
01/30 09:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Commercial and Operational Updates
01/08 09:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Appointment of Chief Legal Officer
12/15 09:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Partnership With The Leapfrog Group
12/04 09:30 am
GlobeNewswire Inc.
Read moreTarget Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday
11/15 12:08 pm
Benzinga
Read moreCorMedix (CRMD) Q3 2023 Earnings Call Transcript
11/14 08:45 pm
The Motley Fool
Read moreCorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
11/14 05:05 pm
GlobeNewswire Inc.
Read moreCorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
11/02 08:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
10/11 08:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
09/08 08:30 am
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
08/30 08:00 am
GlobeNewswire Inc.
Read moreBenzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
08/10 11:00 am
Benzinga
Read moreThe Latest Analyst Ratings for Cormedix
08/10 10:01 am
Benzinga
Read moreCorMedix (CRMD) Q2 2023 Earnings Call Transcript
08/08 05:00 pm
The Motley Fool
Read moreCorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
08/08 07:30 am
GlobeNewswire Inc.
Read moreWhy CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket
06/29 08:18 am
Benzinga
Read moreCorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
06/28 10:57 pm
GlobeNewswire Inc.
Read moreCorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
06/28 04:07 pm
GlobeNewswire Inc.
Read moreAnalyst Ratings for Cormedix
06/21 12:00 pm
Benzinga
Read moreCormedix Inc. To Present At The Jefferies Healthcare Conference
05/30 08:30 am
GlobeNewswire Inc.
Read moreAs CorMedix's DefenCath Moves Forward On Regulatory Path, Analyst Boosts Price Target
05/19 02:09 pm
Benzinga
Read moreWhat 5 Analyst Ratings Have To Say About Cormedix
05/16 09:02 am
Benzinga
Read moreCorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
05/16 07:00 am
GlobeNewswire Inc.
Read moreCorMedix (CRMD) Q1 2023 Earnings Call Transcript
05/15 10:30 pm
The Motley Fool
Read moreCorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
05/01 08:30 am
GlobeNewswire Inc.
Read moreHere's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
04/27 09:55 am
Zacks Investment Research
Read more